Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.73 |
| ▸ | EGFR | P00533 | 5/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
| ▸ | CDK8 | P49336 | 1/20 | 0.64 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 5/20 | 0.53 |
| ▸ | CSF1R | P07333 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15860119 | 0.87 | MAP3K20 (0.56) | BRAFEGFRRETCDK8MAP3K20 | |
| SCHEMBL15859839 | 0.82 | EGFR (0.58) | BRAFEGFRRETMAP3K20MAPK14 | |
| SCHEMBL2289051 | 0.81 | BRAF (0.77) | BRAFEGFRRETABL1BCR | |
| SCHEMBL15859875 | 0.81 | ABL1 (0.56) | BRAFEGFRRETMAP3K20MAPK14 | |
| SCHEMBL2289046 | 0.79 | BRAF (0.72) | BRAFEGFRRETABL1BCR | |
| SCHEMBL15860121 | 0.79 | MAP3K20 (0.59) | BRAFEGFRRETCDK8MAP3K20 | |
| SCHEMBL4786842 | 0.79 | BRAF (1.00) | BRAFEGFRABL1 | |
| SCHEMBL24161460 | 0.76 | ABL1 (0.78) | BRAFEGFRRETABL1BCR | |
| SCHEMBL17420190 | 0.76 | EGFR (0.55) | BRAFEGFRRETABL1BCR | |
| SCHEMBL24161637 | 0.76 | ABL1 (0.77) | BRAFEGFRRETABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9006457-B2 | Reactive ionic liquids | BASF SE (DE) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | BRAF 74/4885EGFR 1148/4885RET 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.